{"product_id":"jubilantpharmova-pestle-analysis","title":"Jubilant Pharmova PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our targeted PESTLE Analysis of Jubilant Pharmova—revealing how political shifts, regulatory pressures, economic trends, and technological advances shape its outlook; buy the full report for an actionable, ready-to-use breakdown that powers smarter investment and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe India–US trade relationship remains critical for Jubilant Pharmova in late 2025; US imports of Indian pharmaceuticals grew ~8% in 2024 to $7.1bn, making tariff or regulatory shifts material for export revenue.\u003c\/p\u003e\n\u003cp\u003eNew tariffs or tighter trade rules could raise export costs for radiopharmaceuticals and allergy products, where margins already face pressure from pricing competition and supply-chain freight increases of ~12% since 2023.\u003c\/p\u003e\n\u003cp\u003eManagement must actively engage in trade monitoring and diversify channels—Europe accounted for ~35% of Jubilant’s international sales in FY2024—to protect market access and preserve competitive pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Policy Reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising government healthcare spending—North America at ~19.7% of GDP and EU average ~10.5% in 2024—drives demand for contract manufacturing and specialty medicines, benefiting Jubilant Pharmova’s CDMO and specialty pharma segments.\u003c\/p\u003e\n\u003cp\u003eShifts in reimbursement for diagnostic imaging and immunotherapies, which saw global immunotherapy sales exceed $150bn in 2024, can materially affect segment margins and R\u0026amp;D ROI.\u003c\/p\u003e\n\u003cp\u003eMonitoring legislative changes in public health budgets and reimbursement frameworks is critical for Jubilant’s long-term revenue forecasts and capacity planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppolitical pressure to cut essential medicine costs in the us and india by proposals like cms rules national health policy jubilant pharmova reconcile rising r spend bn fy2024 with demand for low-cost generics branded drugs. legislative moves on price transparency proposed inflation rebates increase margin requiring operational optimization protect ebitda reported group without quality trade-offs.\u003e\n\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncentives for Domestic Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIndian PLI schemes and Atmanirbhar Bharat initiatives offer Jubilant Pharmova expansion opportunities; the PLI pharma+chem program (approved FY2021–22) targets 13–14% manufacturing growth and disburses incentives over 6 years, supporting API scale-up.\u003c\/p\u003e\n\u003cp\u003eLeveraging PLI, Jubilant can access capital subsidies and tax breaks—India allocated ~Rs 1,45,000 crore for PLI across sectors—reducing API import dependence (India imported ~70% of certain APIs in 2023) and boosting export competitiveness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to multi-year PLI incentives and capex support\u003c\/li\u003e\n\u003cli\u003eBenefit from tax breaks and infrastructure grants\u003c\/li\u003e\n\u003cli\u003eAligns with national push to cut ~70% API import reliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical efforts toward regulatory harmonization such as ich adoption across countries and who reliance models streamline jubilant pharmova global product launches by reducing duplicative filings lowering time-to-market.\u003e\n\u003cpharmonized frameworks cut multi-country clinical trial complexity jubilant cro and cdmo segments can save an estimated in regulatory overhead per program supporting fy2024 revenues crore growth.\u003e\n\u003cphowever political instability in several emerging markets supply disruptions parts of africa threatens consistent enforcement standards and could delay approvals or increase compliance costs.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH\/WHO alignment eases filings across 17+ jurisdictions\u003c\/li\u003e\n\u003cli\u003eEstimated 10–15% regulatory overhead reduction for multi-country trials\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue context: INR 10,461 crore\u003c\/li\u003e\n\u003cli\u003ePolitical instability in emerging markets raises approval and compliance risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phowever\u003e\u003c\/pharmonized\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJubilant Pharmova: PLI boost vs price controls—US $7.1bn imports, EBITDA ~14%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors impacting Jubilant Pharmova include US–India trade dynamics (US imports of Indian pharma ~$7.1bn in 2024), tariff\/regulatory risk, domestic PLI incentives (India PLI allocation ~Rs 1,45,000 crore) aiding API scale-up, rising health budgets (North America ~19.7% of GDP, EU ~10.5% in 2024) boosting CDMO demand, and price-control pressures compressing EBITDA (~14% in FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS imports of Indian pharma (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup EBITDA margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia PLI allocation\u003c\/td\u003e\n\u003ctd\u003e~Rs 1,45,000 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorth America health spend (2024)\u003c\/td\u003e\n\u003ctd\u003e~19.7% GDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Jubilant Pharmova across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform executives, investors, and strategists on risks, opportunities, and scenario-driven actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Jubilant Pharmova that’s easy to drop into presentations or share across teams, enabling quick alignment on external risks, market positioning, and action points during planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs ~60% of Jubilant Pharmova's FY2024 revenue was USD-denominated while costs remained largely INR-based, INR\/USD volatility materially affects margins; a 5% Rupee appreciation in 2024 could trim EBITDA by an estimated 80–120 bps. The company uses forward contracts and options—hedging ~40–70% of near-term FX exposure in 2023–24—to dampen swings. Analysts track quarterly FX translation gains\/losses and monitor real effective exchange rate movements to refine valuation models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, rising global policy rates — India’s repo at 6.5% and comparable developed-market rates around 4–5% — have raised Jubilant Pharmova’s cost of debt, increasing annual interest expenses and tightening margins on capital-intensive sterile injectable expansions projected at INR 1–1.5 billion per facility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal inflation pushed commodity prices up in 2024, with basic chemical and energy costs rising roughly 8–12% year-on-year, increasing Jubilant Pharmova’s input costs for APIs and intermediates.\u003c\/p\u003e\n\u003cp\u003eTo protect margins, Jubilant Pharmova emphasized operational efficiencies and strategic sourcing, targeting \u0026gt;5% cost savings through scale and supply-chain consolidation in FY2024.\u003c\/p\u003e\n\u003cp\u003eThe firm’s contract manufacturing agreements enabled partial cost pass-throughs, supporting stable gross margins near 22–24% in 2024 despite higher raw material and logistics expenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the Radiopharmaceutical Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe global nuclear medicine market reached about USD 8.2 billion in 2024 and is forecasted to grow at ~8–9% CAGR through 2030, offering Jubilant Pharmova’s radiopharma division a sizable addressable market and revenue upside.\u003c\/p\u003e\n\u003cp\u003eRising diagnostic infrastructure investment—notably in North America, Europe, and APAC where PET\/CT capacity expanded ~6–7% in 2023–24—boosts demand for radiopharmaceuticals produced by the company.\u003c\/p\u003e\n\u003cp\u003eRadiopharma is a higher-margin, capital- and regulatory-intensive niche with substantial entry barriers versus generics, supporting sustained pricing power and margin expansion for Jubilant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 market ~USD 8.2B; 8–9% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003ePET\/CT capacity +6–7% in 2023–24\u003c\/li\u003e\n\u003cli\u003eHigher barriers and better margins vs generics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Cost Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprising wages for skilled scientists and technicians in india salary growth north america pharma r salaries up yoy increase jubilant pharmova opex especially cdmo services.\u003e\n\u003cpto retain top-tier biotech talent and sustain innovation jubilant must offer competitive packages while controlling costs finance face pressure as employee-related expenses likely represent a growing share of sg r spend.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndia salary inflation ~8–10% (2024)\u003c\/li\u003e\n\u003cli\u003eNorth America pharma R\u0026amp;D pay +6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eHigher talent costs raise OPEX and R\u0026amp;D expense ratios\u003c\/li\u003e\n\u003cli\u003eNeed balance: competitive pay vs cost control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pto\u003e\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUSD-led revenue (~60%) shields margins despite INR re-rating, higher costs, partial hedges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey economic drivers: USD revenue ~60% of FY2024; 5% INR appreciation could cut EBITDA ~80–120bps; hedging covered ~40–70% (2023–24). Repo ~6.5% (late-2025) lifted borrowing costs for INR 1–1.5bn sterile-capex units. Commodity inflation +8–12% (2024) raised API costs; gross margins held ~22–24% via contract pass-throughs and \u0026gt;5% cost-saves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD rev share (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA hit (5% INR app.)\u003c\/td\u003e\n\u003ctd\u003e80–120bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedge cover (2023–24)\u003c\/td\u003e\n\u003ctd\u003e40–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepo (late-2025)\u003c\/td\u003e\n\u003ctd\u003e6.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommodity inflation (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e22–24%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eJubilant Pharmova PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for Jubilant Pharmova PESTLE analysis; no placeholders or surprises, just the complete file available for instant download after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751670231417,"sku":"jubilantpharmova-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jubilantpharmova-pestle-analysis.png?v=1772233919","url":"https:\/\/matrixbcg.com\/products\/jubilantpharmova-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}